ArticleNeuroradiology2026
Differential atrophy along the longitudinal axis of the hippocampus in Alzheimer's disease and suspected non-Alzheimer's disease pathophysiology (SNAP).
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeCerebrospinal fluid (CSF) biomarkers are increasingly used to support Alzheimer's disease (AD) diagnosis: Alzheimer's Disease continuum (ADc) is defined by abnormal amyloid-beta (Aβ), while Suspected Non-AD Pathophysiology (SNAP) refers to normal Aβ with elevated tau. Given the differential properties along the hippocampal longitudinal axis, this study aimed to evaluate anterior-posterior subregional hippocampal volume differences among ADc, SNAP, and biomarker-negative participants, and their associations with CSF biomarkers and clinical presentation.
methodsData from 1242 participants in the Alzheimer's Disease Neuroimaging Initiative were analyzed. Biomarker-negative participants (n = 234) had normal CSF Aβ42 (≥ 192 pg/ml), total tau (< 93 pg/ml), and phosphorylated tau at threonine 181 (< 23 pg/ml). ADc individuals (n = 784) had abnormal Aβ42, and SNAP (n = 224) showed normal Aβ42 with elevated tau. T1-weighted MRI scans were used to segment the hippocampus into anterior, intermediate, and posterior subregions. Controlling for age, sex, and multiple comparisons, groups were compared using one-way ANOVA, and Pearson correlation coefficients were calculated to assess the relationships between volumetric variables and age, CSF biomarkers, or neuropsychological scores.
resultsADc individuals showed significantly lower total and subregional hippocampal volumes compared with SNAP and biomarker-negative participants (P < 0.001). Normalized volumes to total ipsilateral hippocampal volume revealed greater posterior atrophy (P < 0.001) and relatively higher anterior volume (P < 0.01) in ADc. SNAP and biomarker-negative participants showed stronger correlations between hippocampal volumes and age. Several subregional hippocampal volumes correlated with CSF biomarkers, cognitive performance, neuropsychiatric symptoms, and functional impairment.
conclusionThis study reveals distinct patterns of hippocampal atrophy in ADc and SNAP, enhancing our understanding of their differential pathophysiology and associated clinical features.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.